A5083968212- Medical Imaging Techniques and Applications
- Advanced MRI Techniques and Applications
- Radiopharmaceutical Chemistry and Applications
- Neuroscience and Neuropharmacology Research
- Lanthanide and Transition Metal Complexes
- Cardiac Imaging and Diagnostics
- Functional Brain Connectivity Studies
- Receptor Mechanisms and Signaling
- Neurotransmitter Receptor Influence on Behavior
- Alzheimer's disease research and treatments
- Cancer, Hypoxia, and Metabolism
- Glioma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Treatment of Major Depression
- Advanced Radiotherapy Techniques
- Advanced Neuroimaging Techniques and Applications
- Advanced X-ray and CT Imaging
- Nanoparticle-Based Drug Delivery
- Tuberous Sclerosis Complex Research
- Pancreatic function and diabetes
- Cerebrovascular and Carotid Artery Diseases
- Mitochondrial Function and Pathology
- Pharmacological Receptor Mechanisms and Effects
- Parkinson's Disease Mechanisms and Treatments
- Dementia and Cognitive Impairment Research
Gordon Center for Medical Imaging
2016-2025
Harvard University
2016-2025
Massachusetts General Hospital
2016-2025
Yale University
2010-2024
Medieval Academy of America
2024
Yale Cancer Center
2024
Sorbonne Université
2019
Pitié-Salpêtrière Hospital
2019
Laboratoire d’Imagerie Biomédicale
2019
Emory University
2017
To examine region- and substrate-specific autoradiographic in vitro binding patterns of positron emission tomography tracer [F-18]-AV-1451 (previously known as T807), tailored to allow vivo detection paired helical filament-tau-containing lesions, determine whether there is off-target other amyloid/non-amyloid proteins.We applied phosphor screen autoradiography, nuclear emulsion [H-3]-AV-1451 assays the study postmortem samples from patients with a definite pathological diagnosis Alzheimer...
Objective Recent studies have shown that positron emission tomography (PET) tracer AV-1451 exhibits high binding affinity for paired helical filament (PHF)-tau pathology in Alzheimer's brains. However, the ability of this ligand to bind tau lesions other tauopathies remains controversial. Our goal was examine correlation vivo and postmortem patterns three autopsy-confirmed non-Alzheimer tauopathy cases. Methods We quantified retention [F-18]-AV-1451 performed autoradiography, [H-3]-AV-1451...
In vivo and autopsy evidence supports locus coeruleus MRI measures as proxy of initial TAU deposition amyloid-related memory decline.
Advances in molecular positron emission tomography (PET) have enabled anatomic tracking of brain pathology longitudinal studies normal aging and dementia, including assessment the central model Alzheimer's disease (AD) pathogenesis, according to which TAU begins focally but expands catastrophically under influence amyloid-β (Aβ) mediate neurodegeneration cognitive decline. Initial deposition occurs many years before Aβ a specific area medial temporal lobe. Building on recent work that focus...
Abstract We and others have shown that [ 18 F]-Flortaucipir, the most validated tau PET tracer thus far, binds with strong affinity to aggregates in Alzheimer's (AD) but has relatively low for non-AD tauopathies exhibits off-target binding neuromelanin- melanin-containing cells, hemorrhages. Several second-generation tracers been subsequently developed. F]-MK-6240 F]-PI-2620 are two garnered attention. Our recent data indicated pattern of closely parallels F]-Flortaucipir. The present study...
[F-18]-MK-6240, a novel tau positron emission tomography (PET) tracer recently discovered for the in vivo detection of neurofibrillary tangles, has potential to improve diagnostic accuracy Alzheimer disease. We have examined regional and substrate-specific binding patterns as well possible off-target this on human brain tissue advance towards its validation. applied [F-18]-MK-6240 phosphor screen high resolution autoradiography postmortem samples from patients with definite pathological...
Dopamine transmission abnormalities have been implicated in the etiology of bipolar disorder (BPD). However, there is a paucity receptor imaging studies BPD, and little information available about dopamine system BPD. Reuptake synaptic by transporter (DAT) principal mechanism regulating neurotransmission, often used as marker for presynaptic function. This positron emission tomography (PET) study investigated whether DAT availability differed between BPD healthy control subjects.A total 11...
This study employed simultaneous neuroimaging with positron emission tomography (PET) and functional magnetic resonance imaging (fMRI) to demonstrate the relationship between changes in receptor occupancy measured by PET brain activity inferred fMRI. By administering D2/D3 dopamine antagonist [ 11 C]raclopride at varying specific activities anesthetized nonhuman primates, we mapped associations hemodynamics [cerebral blood volume (CBV)] domains of space, time, dose. Mass doses raclopride...
The ability to noninvasively measure endogenous pancreatic β-cell mass (BCM) would accelerate research on the pathophysiology of diabetes and revolutionize preclinical development new treatments, clinical assessment therapeutic efficacy, early diagnosis subsequent monitoring disease progression. vesicular monoamine transporter type 2 (VMAT2) is coexpressed with insulin in β-cells represents a promising target for BCM imaging. <b>Methods:</b> We evaluated VMAT2 radiotracer...
[F-18]-AV-1451 is a novel positron emission tomography (PET) tracer with high affinity to neurofibrillary tau pathology in Alzheimer's disease (AD). PET studies have shown increased retention patients clinically diagnosed dementia of AD type and mild cognitive impairment regions that are known contain lesions. In vivo uptake has also consistently been observed midbrain, basal ganglia choroid plexus elderly individuals regardless their clinical diagnosis, including normal whose brains not...
The Radiotracer [ 11 C]OMAR was developed for positron emission tomography (PET) imaging of cannabinoid type-1 receptors (CB1R). objectives the present study were to evaluate kinetic analysis methods, determine test–retest reliability, and assess gender differences in receptor availability. Dynamic PET data acquired 10 human subjects, analyzed with one-tissue (1T) two-tissue (2T) compartment models by Logan multilinear (MA1) methods estimate regional volume distribution ( V T ). 2T model...
Chronic wounds affect 12-15% of patients with diabetes and are associated a drastic decrease in their quality life. Here, we demonstrate that purified mature naive B220+ /CD19+ /IgM+ /IgD+ B cells improve healing acute diabetic murine after single topical application. cell treatment significantly accelerated wound closure by 2-3 days wild-type mice 5-6 obese mice. The led to full 43% chronic wounds, as compared only 5% saline-treated controls. Applying equivalent numbers T or disrupted...
<h3>Importance</h3> Major depressive disorder (MDD) might involve dopamine (DA) reductions. The DA transporter (DAT) regulates clearance and neurotransmission is sensitive to levels, with preclinical studies (including those involving inescapable stressors) showing that DAT density decreases when signaling reduced. Despite data, evidence of reduced in MDD inconclusive. <h3>Objective</h3> Using a highly selective positron emission tomography (PET) tracer ([<sup>11</sup>C] altropane),...
<sup>18</sup>F-T807 is a PET radiotracer developed for imaging tau protein aggregates, which are implicated in neurologic disorders including Alzheimer disease and traumatic brain injury (TBI). The current study characterizes pharmacokinetics human subjects using dynamic metabolite-corrected arterial input functions. <b>Methods:</b> Nine (4 controls, 3 with history of TBI, 2 mild cognitive impairment due to suspected disease) underwent up 120 min after bolus injection blood sampling. Total...
Abstract Glycogen synthase kinase‐3 (GSK‐3) regulates multiple cellular processes in diabetes, oncology, and neurology. N ‐(3‐(1H‐1,2,4‐triazol‐1‐yl)propyl)‐5‐(3‐chloro‐4‐methoxyphenyl)oxazole‐4‐carboxamide (PF‐04802367 or PF‐367) has been identified as a highly potent inhibitor, which is among the most selective antagonists of GSK‐3 to date. Its efficacy was demonstrated modulation tau phosphorylation vitro vivo. Whereas kinetics PF‐367 binding brain tissues are too fast for an effective...
Alzheimer's disease (AD) is characterized by diffuse amyloid-β (Aβ) and phosphorylated Tau (p-Tau) aggregates as well neuroinflammation. Exogenously-induced 40 Hz gamma oscillations have been showing to reduce Aβ p-Tau deposition presumably via microglia activation in AD mouse models. We aimed translate preclinical data on gamma-induction patients means of transcranial alternating current stimulation (tACS). Four participants with mild-to-moderate received 1 h daily (gamma) tACS for 4 weeks...
A dopaminergic response to alcohol in humans has not been demonstrated consistently with positron emission tomography (PET). We hypothesized that the effect of on striatal dopamine (DA) release may be anatomically heterogeneous between subjects. Our approach was identify voxels exhibited alcohol-induced DA responses within striatum, and determine relationships alcohol-related behavior.A novel method developed examine anatomic extent magnitude across Thirteen healthy control subjects...
Background Several lines of evidence link cannabinoid ( CB ) type 1 receptor‐mediated endogenous (e signaling to the etiology alcohol dependence AD ). However, date, only peripheral measures e function have been collected in living humans with and no human vivo data on potentially critical role brain receptor published. This is an important gap literature, because recent therapeutic developments suggest that these receptors could be targeted for treatment . Methods Medication‐free...
Abstract Lorlatinib (PF-06463922) is a next-generation small-molecule inhibitor of the orphan receptor tyrosine kinase c-ros oncogene 1 (ROS1), which has domain that physiologically related to anaplastic lymphoma (ALK), and undergoing Phase I/II clinical trial investigations for non-small cell lung cancers. An early goal measure concentrations this drug in brain tumour lesions cancer patients, as penetration blood–brain barrier important optimal therapeutic outcomes. Here we prepare both 11...